Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol
Clinical Infectious Diseases · 15.10.2024 · 79 (4) · 871-887
DOI: 10.1093/cid/ciad666 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Clinical Infectious Diseases, online erschienen am 31.10.2023. Verfasst von Dana de Kretser und 37 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Zealand Health Research Council, Australian National Health and Medical Research Council, United Kingdom National Institute for Health and Care Research.
Abstract (Originalsprache)
Background
Staphylococcus aureus bloodstream infection (bacteremia) is traditionally treated with at least 2 weeks of intravenous (IV) antibiotics in adults, 3–7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia (SAB) with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients. Protocol The early oral switch (EOS) domain of the S. aureus Network Adaptive Platform (SNAP) trial will assess early switch to oral antibiotics compared with continued IV treatment in clinically stable patients with SAB. The primary endpoint is 90-day all-cause mortality. Hospitalised SAB patients are assessed at platform day 7 ±2 (uncomplicated SAB) and day 14 ±2 (complicated SAB) to determine their eligibility for randomization to EOS (intervention) or continued IV treatment (current standard of care).
Discussion
Recruitment is occurring in the EOS domain of the SNAP trial. As of August 2023, 21% of all SNAP participants had been randomized to the EOS domain, a total of 264 participants across 77 centers, with an aim to recruit at least 1000 participants. We describe challenges and facilitators to enrolment in this domain to aid those planning similar trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
- Department of Infectious Diseases University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
- Department of Infection Services, Wellington Regional Hospital, New Zealand.
- Telethon Kids Institute, Wesfarmers Center of Infectious Diseases and Vaccines, The University of Western Australia, Perth, Australia.
- Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Center, Montreal, Canada.
- Department of Infectious Diseases, Eastern Health, Box Hill, Australia.
Förderung
- New Zealand Health Research Council
- Australian National Health and Medical Research Council
- United Kingdom National Institute for Health and Care Research
- Te Niwha Infectious Diseases Research Fund
- Advancing Queensland Clinical Fellowship
- National Health and Medical Research Council
- CIHR
- Singapore National Medical Research Council
Zitieren
APA
de Kretser, D., Mora, J., Bloomfield, M., Campbell, A., Cheng, M. P., Guy, S., Hensgens, M., Kalimuddin, S., Lee, T. C., Legg, A., Mahar, R. K., Marks, M., Marsh, J., McGlothin, A., Morpeth, S. C., Sud, A., Ten Oever, J., Yahav, D., Bonten, M., …, & SNAP Trial Group (2024). Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clinical Infectious Diseases, 79(4), 871-887. https://doi.org/10.1093/cid/ciad666
Vancouver
de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, et al. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clinical Infectious Diseases. 2024;79(4):871-887. doi:10.1093/cid/ciad666
BibTeX
@article{deKretser2024,
author = {de Kretser, Dana and Mora, Jocelyn and Bloomfield, Max and Campbell, Anita and Cheng, Matthew P and Guy, Stephen and Hensgens, Marjolein and Kalimuddin, Shirin and Lee, Todd C and Legg, Amy and Mahar, Robert K and Marks, Michael and Marsh, Julie and McGlothin, Anna and Morpeth, Susan C and Sud, Archana and Ten Oever, Jaap and Yahav, Dafna and Bonten, Marc and Bowen, Asha C and Daneman, Nick and van Hal, Sebastiaan J and Heriot, George S and Lewis, Roger J and Lye, David C and McQuilten, Zoe and Paterson, David L and Owen Robinson, J and Roberts, Jason A and Scarborough, Matthew and Webb, Steve A and Whiteway, Lynda and Tong, Steven Y C and Davis, Joshua S and Walls, Genevieve and Goodman, Anna L and SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee, SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee and SNAP Trial Group, SNAP Trial Group},
title = {Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {79},
number = {4},
pages = {871--887},
doi = {10.1093/cid/ciad666}
}
EUVIMED